Spero Posts $44.3M Q3 Loss, Far Exceeding Prior Quarter's $9.6M
SPRO is trading near its 52-week low of $0.961 (4.1% above the low).
Summary
Spero reported a $44.3 million third-quarter loss, a sharp widening from the $9.6 million net loss it posted for Q2, with the wider loss tied to an SP001 licensing payment. The company has no product revenue and is funding itself off a $105 million royalty financing that management said extends cash runway into 2029, so the size of this quarter's loss matters more than usual for a name trading near its 52-week low. A Phase 2 trial is planned for Q2 2027. The loss lands alongside recent board turnover — Patrick Vink resigned November 10 and William Ho joined the board — and COO Timothy Keutzer's planned retirement at year-end. The company also has a $300 million shelf and a $100 million Jefferies at-the-market program in place, giving it a ready channel to raise equity if the burn continues at this pace.
At the time of this announcement, SPRO was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.2M. The 52-week trading range was $0.96 to $3.08. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.